The immuno-oncology condition center is a comprehensive resource for clinical news and expert insights on immuno-oncology. Read more at OncLive.
July 22nd 2025
Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.
July 20th 2025
The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.
July 17th 2025
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.
July 13th 2025
July 8th 2025
Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.
July 7th 2025
PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.
July 6th 2025
The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.
July 4th 2025
Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.
July 3rd 2025
CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.
Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.
Douglas B. Johnson, MD, MSCI, discusses clinical questions, unmet needs, and exciting therapeutic developments with immuno-oncology in melanoma.
July 2nd 2025
Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.
July 1st 2025
Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.
Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.
June 30th 2025
The combination of zelenectide pevedotin and pembrolizumab was safe and produced antitumor activity in cisplatin-ineligible urothelial cancer.
June 26th 2025
Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.
June 25th 2025
Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.
June 20th 2025
Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.